SOUTH SAN FRANCISCO, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the presentation of positive preclinical data supporting development of its novel, non-peptidic cathepsin L inhibitors as anticancer agents. The data were presented today at the 102nd Annual Meeting of the American Association of Cancer Research in Orlando, Florida.
